CTLA4 and glioblastoma: In an in vivo immunocompetent CSC-derived GBM model, Saha et al. revealed that a triple combination of oncolytic herpes simplex virus expressing IL-12, anti-PD-1 and anti-CTLA-4 effectively cured tumor, whereas neither single nor dual combination was effective in overcoming the immune suppression in GBM [329].